Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Cost of Revenue: 2018-2025

Historic Cost of Revenue for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to $9.4 million.

  • Akebia Therapeutics' Cost of Revenue fell 33.74% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.3 million, marking a year-over-year decrease of 23.07%. This contributed to the annual value of $63.2 million for FY2024, which is 14.80% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Cost of Revenue of $9.4 million as of Q3 2025, which was down 5.40% from $9.9 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Cost of Revenue ranged from a high of $52.5 million in Q2 2021 and a low of -$3.4 million during Q4 2022.
  • In the last 3 years, Akebia Therapeutics' Cost of Revenue had a median value of $17.0 million in 2024 and averaged $14.9 million.
  • Per our database at Business Quant, Akebia Therapeutics' Cost of Revenue plummeted by 107.20% in 2022 and then skyrocketed by 644.33% in 2023.
  • Akebia Therapeutics' Cost of Revenue (Quarterly) stood at $47.6 million in 2021, then plummeted by 107.20% to -$3.4 million in 2022, then soared by 644.33% to $18.7 million in 2023, then climbed by 9.11% to $20.4 million in 2024, then plummeted by 33.74% to $9.4 million in 2025.
  • Its Cost of Revenue was $9.4 million in Q3 2025, compared to $9.9 million in Q2 2025 and $7.6 million in Q1 2025.